ADA and severe combined immunodeficiency: The first attempts at gene therapy in the field of IEIs began in the ’90s and targeted ADA-SCID and X-SCID, caused by defects in the common gamma chain of IL-2 receptor, and subsequently chronic granulomatous disease and Wiskott–Aldrich syndrome196–202.